Lakefront Biotherapeutics NV: all 116 studies
Page 2 of 2. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01384422Phase 2
- GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic StudyCompletedNCT01336244Phase 1
- Oral Bioavailability of Two Solid Formulations of GLPG0259.CompletedNCT01322451Phase 1
- GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid TumorsCompletedNCT01313598Phase 1
- First-in-Human Single Ascending and Multiple Dose of GLPG0778CompletedNCT01278108Phase 1
- Oral Bioavailability of GLPG0555 in Different Solid FormulationsCompletedNCT01278095Phase 1
- GLPG0259 in Methotrexate-refractory Rheumatoid ArthritisCompletedNCT01211249Phase 2
- Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy SubjectsCompletedNCT01208753Phase 1
- First-in-Human Single Ascending and Multiple Dose of GLPG0634CompletedNCT01179581Phase 1
- First-in-Human Single Ascending Dose of GLPG0492CompletedNCT01130818Phase 1
- Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)TerminatedNCT01039103Phase 2
- GLPG0259 Solid Formulation Bioavailability and Food EffectCompletedNCT01024517Phase 1
- First-in-Human Single Ascending and Multiple Dose of GLPG0555CompletedNCT01023321Phase 1
- GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy SubjectsCompletedNCT00989703Phase 1
- First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187CompletedNCT00928343Phase 1
- First-in-Human Single Ascending and Multiple Dose of GLPG0259CompletedNCT00905138Phase 1